An overview of emerging immunotargets of genitourinary tumors

Rodolfo Montironi, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Francesco Massari, Marc R. Matrana, Holger Moch, Marina Scarpelli

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.

Original languageEnglish (US)
Pages (from-to)750-756
Number of pages7
JournalCurrent Drug Targets
Volume17
Issue number7
StatePublished - Jun 1 2016

Fingerprint

Tumors
Neoplasms
Weapons
Lymphocytes
Macrophages
Immune system
Neoplasm Antigens
Renal Cell Carcinoma
Drug Resistance
Urinary Bladder Neoplasms
Immunotherapy
Immunosuppression
Immune System
Prostatic Neoplasms
Neutrophils
B-Lymphocytes
Cells
T-Lymphocytes
Antigens
Pharmaceutical Preparations

Keywords

  • Genitourinary tumors
  • Immunotherapy
  • Lymphocytes
  • Macrophages
  • Neutrophils

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Montironi, R., Santoni, M., Cheng, L., Lopez-Beltran, A., Massari, F., Matrana, M. R., ... Scarpelli, M. (2016). An overview of emerging immunotargets of genitourinary tumors. Current Drug Targets, 17(7), 750-756.

An overview of emerging immunotargets of genitourinary tumors. / Montironi, Rodolfo; Santoni, Matteo; Cheng, Liang; Lopez-Beltran, Antonio; Massari, Francesco; Matrana, Marc R.; Moch, Holger; Scarpelli, Marina.

In: Current Drug Targets, Vol. 17, No. 7, 01.06.2016, p. 750-756.

Research output: Contribution to journalArticle

Montironi, R, Santoni, M, Cheng, L, Lopez-Beltran, A, Massari, F, Matrana, MR, Moch, H & Scarpelli, M 2016, 'An overview of emerging immunotargets of genitourinary tumors', Current Drug Targets, vol. 17, no. 7, pp. 750-756.
Montironi R, Santoni M, Cheng L, Lopez-Beltran A, Massari F, Matrana MR et al. An overview of emerging immunotargets of genitourinary tumors. Current Drug Targets. 2016 Jun 1;17(7):750-756.
Montironi, Rodolfo ; Santoni, Matteo ; Cheng, Liang ; Lopez-Beltran, Antonio ; Massari, Francesco ; Matrana, Marc R. ; Moch, Holger ; Scarpelli, Marina. / An overview of emerging immunotargets of genitourinary tumors. In: Current Drug Targets. 2016 ; Vol. 17, No. 7. pp. 750-756.
@article{7e60a8a1a8c0437ba2acbc232a87f5fc,
title = "An overview of emerging immunotargets of genitourinary tumors",
abstract = "Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.",
keywords = "Genitourinary tumors, Immunotherapy, Lymphocytes, Macrophages, Neutrophils",
author = "Rodolfo Montironi and Matteo Santoni and Liang Cheng and Antonio Lopez-Beltran and Francesco Massari and Matrana, {Marc R.} and Holger Moch and Marina Scarpelli",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "17",
pages = "750--756",
journal = "Current Drug Targets",
issn = "1389-4501",
publisher = "Bentham Science Publishers B.V.",
number = "7",

}

TY - JOUR

T1 - An overview of emerging immunotargets of genitourinary tumors

AU - Montironi, Rodolfo

AU - Santoni, Matteo

AU - Cheng, Liang

AU - Lopez-Beltran, Antonio

AU - Massari, Francesco

AU - Matrana, Marc R.

AU - Moch, Holger

AU - Scarpelli, Marina

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.

AB - Emerging immunotherapies targeting immune checkpoints and tumor associated antigens are leading to important clinical advances and providing a new weapon in patients with prostate (PCa) and bladder cancer (BC) and, in particular, with renal cell carcinoma (RCC). The possibility to integrate these agents in the current therapeutic scenario or genitourinary tumors, both in sequential or combined approaches, relies on a more profound comprehension of the protumorigenic activity of the immune system and of the mechanisms of cancer-related immunosuppression. In this regards, neutrophils, T and B lymphocytes and tumor-associated macrophages (TAMs) are implicated in the pathogenesis, progression and development of drug resistance in genitourinary tumors. This review is an overview on the recent insights concerning the role of immune cells in this context.

KW - Genitourinary tumors

KW - Immunotherapy

KW - Lymphocytes

KW - Macrophages

KW - Neutrophils

UR - http://www.scopus.com/inward/record.url?scp=84964296772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84964296772&partnerID=8YFLogxK

M3 - Article

C2 - 26648079

AN - SCOPUS:84964296772

VL - 17

SP - 750

EP - 756

JO - Current Drug Targets

JF - Current Drug Targets

SN - 1389-4501

IS - 7

ER -